4 stories mentioning IMVT
Every FINWIRES story that references IMVT, newest first.
Immunovant (IMVT) has an average rating of buy and mean price target of $46.77, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $33.81, Change: $-0.34, Percent Change: -1.00%
Healthcare stocks were mixed late Wednesday afternoon, with the NYSE Healthcare Index up 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.2%.The iShares Biotechnology ETF (IBB) rose 1.9%.In corporate news, Cigna (CI) shares fell 2.5% after Deutsche Bank downgraded the stock to hold from buy and cut its price target to $302 from $303.Medtronic (MDT) said Wednesday it is planning to acquire medical technology firm SPR Therapeutics for an upfront cash payment of about $650 million. Shares were down 0.8%.Personalis (PSNL) shares jumped 12% after the company said its NeXT personal minimal residual disease test has been approved for expanded coverage by the US Centers for Medicare & Medicaid Services' Molecular Diagnostic Services Program.Immunovant (IMVT) shares surged 35% after the firm said its cash and cash equivalents were about $902.1 million as of March 31, providing runway for announced indications through the potential commercial launch of IMVT-1402 in Graves' disease.
Healthcare stocks were lower Wednesday afternoon, with the NYSE Healthcare Index decreasing 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.2%.The iShares Biotechnology ETF (IBB) rose 1.9%.In corporate news, Medtronic (MDT) said Wednesday it is planning to acquire medical technology firm SPR Therapeutics for an upfront cash payment of about $650 million. Medtronic shares were down 1%.GSK (GSK) said Wednesday it has started negotiations with the pan-Canadian Pharmaceutical Alliance for the use of Blenrep to treat adults with relapsed or refractory multiple myeloma, a type of blood cancer. GSK shares were fractionally higher.Immunovant (IMVT) shares surged 33% after it said Wednesday its cash and cash equivalents were about $902.1 million as of March 31, providing runway for announced indications through the potential commercial launch of IMVT-1402 in Graves' disease.
Immunovant (IMVT) said Wednesday its cash and cash equivalents were about $902.1 million as of March 31, providing runway for announced indications through the potential commercial launch of IMVT-1402 in Graves' disease.Shares climbed more than 33%, with intraday trading volume rising to over 14.8 million from a daily average of roughly 1.4 million.Dorian LPG (LPG) shares jumped 12% amid heavy trading after the company reported a year-over-year surge in fiscal Q4 adjusted earnings and revenue on Wednesday.More than 1.16 million shares of the company traded intraday compared with a daily average of about 523,000.Price: $35.17, Change: $+8.88, Percent Change: +33.77%